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Abstract 
Tri-block copolymer poloxamers are successfully employed for reducing 
adsorption of proteinous molecules onto hydrophobic surfaces, which will protect them 
from quick engulfing by macrophages. For sustained systemic circulation of hydrophobic 
drug carriers, particle surfaces need suitable modification for avoiding phagocytosis and 
this can be successfully done by poloxamers. They can affect the drug release profile, 
which makes them a very promising agent for targeted delivery. This review discusses 
the structure, characteristics and advantages of poloxamers. Poloxamer adsorption onto 
hydrophobic surfaces and adlayer thickness, relative phagocytic uptake and drug release 
profiles of coated drug loaded particles have been described in detail.  
 
Keywords: poloxamer; micelle; drug release; surface modification ; nanoparticles; 
microparticles. 
____________________________________ 
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* Correspondance: shubhro.du@gmail.com; Fax:+36-88624038 ; Tel : +36204843689. 
1. Introduction 
Since 1980s, scientists have been trying to develop potent drug carriers. The 
primary cause behind tremendous development of medical industry is recognizing 
essentiality for developing current therapies for drugs already marketed and yet to be 
marketed. Drugs face tremendous hindrance inside the human body that needs to get over 
so that they can arrive at the target site(s). If they fail to reach, they cannot execute their 
biological function(s). The plasma proteins of our body adsorb  exogenous particles 
which is very significant part of defense mechanism of the human body
1, 2, 3
. Our body 
clears foreign materials with the help of MPS
4, 5, 6, 7, 8, 9
. Non-ionic surfactants are now in 
widespread applications in the pharmaceutical sciences for the coating of surfaces to 
facilitate drug targeting. Sustainable circulation can be obtained by proper modification 
of hydrophobic NPs and MPs which will help them fending off  phagocytosis
10
. 
Poloxamers are block copolymers
11, 12, 13, 14
. They have hydrophilic ethyleneoxide (EO) 
and hydrophobic propyleneoxide (PO) units. Polymer chain PEO and PPO blocks form 
A-B-A type structure. This structure helps them showing surfactant characters. They also 
have the capability of interacting with hydrophobic particles, biological membranes, 
etc.
15, 16, 17
.  
Several reviews have been published in the last decade on the application of 
poloxamers for drug delivery
18, 19
. Kabanov et al. in 2002 
20
 also reviewed drug and gene 
delivery, and described poloxamer micelles and micellar drug formulations, drug release 
from micelles and pharmacokinetic and biodistribution of poloxamers. Brain and oral 
bioavailability of poloxamer was also discussed. In 2008, Batrakova et al. published a 
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review on drugs and genes delivery using poloxamers
21
. Micellar formulations and 
unimer-associated biological response modifying effects of poloxamers were described in 
that study showing exceptional potentiality of application in pharmaceutical industries. 
Multiple effects of poloxamers in multidrug resistance (MDR) cells were also 
highlighted. To the best of our knowledge, no reviews have been published focusing on 
surface modification of hydrophobic drug carriers, adsorption isotherm, adlayer thickness 
and drug delivery profile of poloxamer coated hydrophobic drug carriers. 
 
2. Structure and characteristics of poloxamers 
Poloxamer (also known as “Pluronic”) is a triblock amphiphilic copolymer of EO 
and PO. The simplest structure is: (EO)x–(PO)y–(EO)x (Figure 1). Unit number in 
poloxamers (e.g. x and y) can be varied.                                                                                                                                                                 
Poloxamer synthesis is simple and can be done by adding monomers sequentially. 
Preferred catalyst is alkaline type e.g. KOH, NaOH, etc.
22
. Initiation step is the 
polymerization of the PO block. After that PEO chains grow on the two sides of PPO 
chain. Table 1 shows characteristics of some poloxamers of BASF Corporation, which 
have been discussed in this review. Poloxamers having various EO (x) and PO units (y) 
are characterized by their own HLB ( hydrophilic-lipophilic balance)
23
. 
The most important benefits of these compounds in surface modification of drug 
carrier particles are:  
(1) They have amphiphilic structures and show surfactant behavior. So, it is possible to 
improve hydrophobic surface’s solubility in aqueous solution. The miscibility of the 
substances having various hydrophobicities can also be improved. The control of various 
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amphiphilic property is possible with controlled use of blocks length (structural control) 
and temperature
24, 25
.  
(2) These compounds have low toxicity and lack of immunogenic activity
26, 27, 28
.  
(3) They can affect the drug release profile, which makes them very potent constituents 
existing in the field of controlled drug delivery. 
(4) In water, above critical micelle concentration (CMC) and temperature (CMT), 
poloxamer micelle formation is observed
29, 30, 31, 32, 33
. Poloxamer micelles are potential 
carriers of different types of drugs. 
Poloxamers have much more advantageous applications that are not being 
mentioned here, since they are not relevant to the area of our review.  
 
Micellization  
Individual molecules (also known as ‘unimers’) of amphiphilic block copolymers 
generally have the tendency of being assembled to different micellear conformation in 
water when the concentration is higher than CMC. This process is known as 
‘micellization’
34, 35, 36
. Simplest definition of CMC is concentration at which micelle 
formation takes place. Poloxamer’s CMC is highly dependent on the length of its two 
block. Increase in PPO chain length elevates the overall hydrophobicity.  It leads to the 
segregation of PPO chains inside the micelle core
37, 38, 39
. Consequently, the CMC 
decreases with the increase in PPO chain length
40
. Conversely, increasing PEO block 
length will reduce core hydrophobicity destabilizing the micelle. Therefore, enhancement 
of PEO block length will increase the CMC
40, 41
. 
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Common methods used for determining CMC of poloxamers are: viscosimetry 
42
, 
surface tension measurements
43
, chromatographic analysis
44
, small angle neutron 
scattering (SANS)
45
, small angle X-ray scattering (SAXS)
46
, light scattering
47
, 
differential scanning calorimetry
48
, acoustic measurements
49
, etc. Typically, poloxamers 
that are used to deliver different drugs possess CMC in the range 1 µM-1 mM
20
. 
The usual diameter for poloxamer micelles ranges between 10 nm and 200 nm
50
. 
Micelles can have different shapes: sphere, rod, lamellar, etc. The micelle shapes mainly 
depend on the length of the PEO and PPO chains. Concentration of poloxamer and 
temperature also play significant role in the formation of different shapes. Every 
poloxamer micelle consists of PEO shell and PPO core. After reaching CMC, the number 
of polymers existing in micelle is known as ‘aggregation number’
51
. The sphere-shaped 
micelles generally show aggregation numbers ranging from few to more than hundred. 
PPO core has the ability to act like ‘pool’. It offers hydrophobic drugs to incorporate 
inside the micelle(s). This process is termed as ‘solubilization’
52
. 
 
3. Advantages of tri-block poloxamers over its PEO block 
For modification of hydrophobic surfaces, poloxamers show advantages over 
hydrophilic PEO. PPO being hydrophobic, a polymer composed of PO blocks alone is 
not used for the modification of hydrophobic polymeric surfaces. Poloxamers bind to the 
hydrophobic surface(s) in a more stable way by adapting their structure due to having 
both PEO and PPO chains. On the other hand, PEO alone binds with loose association 
and possesses high dynamicity. Surface-adhering patterns of PEO polymer and 
copolymer having PEO were investigated by Tan et al.
53
. The protein adsorption to 
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polystyrene (PS) colloids treated with PEO or poloxamer 338 (P338) was compared. If 
PEO chain is long, it resists proteins more than that having shorter chain. Thus, it was 
expected that after treating with PEO, improved or leastwise same effect can be observed 
like that of P338 in case of stable attachment for both of them. P338 coated PS has very 
low protein uptake
54
. On the other hand, protein uptake pattern by PEO treated and 
untreated compounds cannot be distinguished. It was concluded that it is easy for 
protein(s) to be adsorbed on the particles by dislocating homopolymer PEO. In case of 
P338 coating, dislocation by protein(s) is not so easy resulting in intact seam. For 
hydrophobic compounds, attraction is weak for homopolymer PEO and stronger for 
copolymer poloxamers.  
 
4. Benefits of poloxamers in drug formulation 
Different poloxamer excipients have been extensively used in pharmaceutical 
industries
55
. They are used as emulsifier
56
, solubilizer for hydrophobic drugs
57
 and 
suspension stabilizer. They also find application in parenteral dosage forms
58
. 
Intravenous formulation of poloxamer 188 (P188) is being marketed by the name 
RheothRx injection. It finds application in the clinical studies. An example of application 
is the thrombolysis in myocardial infarction. Poloxamers can serve different purposes: 
plasticizer, wetting agent, lubricant, etc. They have been using to formulate gel since they 
exhibit thermoreversible gelation in solid dosage forms, however this topic is not the 
object of the present review.  
In a thorough review Moghimi et al.
59
 studied poloxamer application in 
nanoparticle engineering and medicine, such as long-circulating particles, macrophage 
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stimulation, inhibition of multidrug resistance and adjuvant activities, as well as 
antithrombotic, haemorheological activities, cell membrane sealing, phagocyte activation 
and neutrophil degranulation. 
As mentioned before, poloxamer helps drug loaded NPs/MPs to become stealth. 
In previous decades, some interesting studies have been published showing the higher 
existence period of poloxamer in the bloodstream with lower phagocytic uptake
60, 61, 62, 63
. 
Poloxamer coated NPs/MPs are not recognized by macrophages and hence not engulfed 
by them. Macrophageal uptake study for P188 coated and uncoated PLGA NPs was made 
by RAW 264.7 cell lines
64
. Prussian blue staining detected existence of NPs inside cells. 
Uncoated NPs subjected to cell showed blue staining which was the indication of uptake 
by macrophages. On the other hand, same test didn’t show any stain indicating non-
biorecognitive properties of P188 coated NPs. These results confirmed the potential to 
prolong NP circulation when administered in vivo. Further, uptake study using normal 
liver cells showed a dose dependent uptake of NPs functionalized by P188. Thus 
controlled adsorption may enlarge the binding of the stabilizer onto NPs. 
Poloxamer coating is also useful for drug delivery to regional lymph nodes
65, 66
. 
Therapeutic and diagnostic agents can be delivered to the regional lymph nodes using 
biodegradable poloxamer coated nanospheres following interstitial administration
67
. It 
was established that poloxamer coated PLGA NPs are suitable for diagnostic and 
therapeutic applications in clinical and experimental medicine
67
. NPs modified with 
poloxamers showed improved lymphatic uptake (11 %) compared to the control NPs (3 
%) in rat. Successful delivery to lymphatic system was also observed by Sanjula et al., 
who investigated lymphatic uptake of carvedilol-loaded NPs using male Wister rat
68
. 
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Modified PS MPs with P407 were found to be efficient for bone marrow 
application in rabbit
69
. Approximately 50% deposition of the injected MPs in the bone 
marrow of rabbits was measured. The uptake by marrow endothelial cells suggests that a 
specific interaction mechanism enables the penetration through the steric repulsive barrier 
of the cell surface
69
. In section 6.3, delivery to brain, heart, liver, spleen, lungs and 
kidneys by poloxamer coated particles have also been discussed. Overall, it can be 
concluded that poloxamer coating can find widespread application for drug delivery in 
various parts of the body. 
 
5. Adsorption pattern and adlayer thickness of poloxamers 
Poloxamers readily dissolve in water. They are also soluble in many organic 
solvents. Based on the preparation method of hydrophobic NPs and MPs, they can be 
added in a different way and stage of preparation for the modification of hydrophobic 
surfaces. 
By increasing the hydrophobicity of substrate surface, the binding between 
poloxamer and substrate is enhanced
54
. It is well known and can be easily understood that 
adsorption pattern is strongly dependent on the nature of the surface of a particle. 
Hydrophobic PPO has much stronger attraction for hydrophobic surface(s). Conversely, 
hydrophilic PEO has stronger attraction for water and extends towards aqueous phase. In 
general, the adsorption of poloxamer onto a hydrophobic polymeric nano- or 
microparticle surface is shown in Figure 2. When concentration is small, poloxamer 
molecules are adsorbed singly onto hydrophobic polymers. The result is monolayer 
formation on the substrate in which PEO blocks build “mushroom-type” conformation 
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(Figure 2c)
70
. Nevertheless, efficient steric stabilization is observed for a denser 
adsorption layer of poloxamer (Figure 2a). It means when the surface concentration is 
comparatively high, extension of PEO blocks is stronger, which will eventuate “brush-
type” conformation (Figure 2b) in accordance with Gennes et al.
71
. It is interesting to note 
that adlayer thickness is strongly affected by hydrophobicity and used poloxamer’s HLB. 
P188 showed 20 nm adlayer onto PLGA NPs. At concentration close to or higher than 
CMC, thicker layer growth is observed because of hemimicelle adsorption
72
. The adlayer 
thickness depends on the method
53
. For coating PS with F108, field flow fractionation 
method gave higher adlay r thickness than photon correlation spectrophotometer (PCS) 
method. 
Poloxamer adsorption on hydrophobic drug carriers increases the carrier’s 
diameter and broadens the size distribution. The effect  of surface characters on sterically 
stable PS MPs was investigated by mouse peritoneal macrophages
73
. Various poloxamers 
and poloxamine were applied to coat PS MPs, and the adlayer thickness varied between 
3.5-15.8 nm depending on the conditions. For lower concentration of P338 (0.01%), 
adsorption layer was almost 12 nm thick, while it was almost 16 nm at high concentration 
(2%)
73
.  
A sharp plateau was found for adsorption isotherm of F68 onto PLGA NPs when 
the concentration was under the CMC
72
. This result was expected and agreed with the 
study performed by Kayes et al.
74
 whose plateau adsorption value was close to 
10×10
−4
g/m
2
. For PS particles, Tadros et al.
75
 and Baker et al.
76
 found about (8.5 and 
9.5)×10
−4
g/m
2
 plateau-adsorption value respectively, which coincide with the value 
obtained by Santander-Ortega
72
, although just below the CMC the isotherm suffers from 
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a little change. AFM studies revealed that homogeneous layers are not always formed by 
poloxamers. As mentioned before, under certain conditions nonionic surfactants show the 
tendency to construct micelles. That is why sometimes steep-isotherm can be obtained, 
nevertheless there is available theoretical explanation for them in the literature
77,78
. 
Isotherm curve alteration can be attributed to hemimicelle adsorption on PLGA 
particles
72
. The calculated adlayer thickness was around 20 nm measured using PCS. For 
a PS latex having 56 nm diameter, Baker et al.
76
 obtained lower thickness which was only 
6 nm using the identical polymer and optical measurement technique. The adsorption of 
poloxamer on hydrophobic surface is based on the hydrophobic attraction among PPO 
chain and the target surface. Lower hydrophobicity of PLGA related to PS might result in 
less compact adlayer onto PLGA surface by poloxamer. 
The adsorption isotherms of PS NPs with P407 were  measured for NPs of diameters 40 
nm, 70 nm and 137 nm (Figure 3)
79
.They follow a Langmuirian-type profile initially 
showing steep slope, when equilibrium surfactant concentration is low, i.e. below 0.4 
mg/ml. Above certain equilibrium concentration, an adsorption plateau is observed. The 
plateau values greatly agree with the results of another study
80
 using the same type of 
adsorption system(s). P407 plateau adsorption value on NPs can be seen from Table 2. 
0.19, 0.16 and 0.18 µmol/m
2
 of P407 was adsorbed per surface unit for the 137 nm, 70 
nm and 40 nm particles, respectively (Figure 3). These results are in accordance with  
that obtained by Faers et al.
81
. Stolnik et al.
79
 also measured adlayer depth for every 
sampling point of isotherm. The hydrodynamic adlayer thickness for PS NPs of diameters 
137 nm, 70 nm and 40 nm coated with poloxamer is also shown in Table 2
79
 (obtained 
using PCS). 
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Table 3
79
 lists the values of chosen points on isotherm showing how P407 adsorbs 
on 40 nm PS NPs. It illustrates conformational changing of molecules onto NPs for the 
increase in quantity of P407 adsorbed. In case of adsorption of low amounts of P407 
having less surface coverage, area counted for single PEO chain was larger. Adlayer 
thickness was also low indicating the absence of dense packing for P407 onto PS NPs. 
This less dense packing allows more space for lateral spreading of PEO. The surface is 
more crowded, when the amount of poloxamer adsorbed is higher, and the area occupied 
by single P407 decreases, although the adlayer becomes thicker. It is the indication of 
close packing of PEO chains. It also suggests perpendicular extension of PEO chains 
from NP surfaces. 
In our most recent experiments (not published yet), we have investigated 
poloxamer adsorption onto PLGA NPs co-encapsulating model drug human serum 
albumin and magnetite. Double emulsion solvent evaporation method was used for NP 
preparation. Different concentrations of poloxamer F68 (0.25, 0.5 and 1% wt/vol) were 
used to coat the NPs which were redispersed in phosphate buffered saline (PBS) solution 
before the addition of poloxamer. The attachment of poloxamer onto PLGA surface was 
checked by size measurement carried out by Zetasizer Nano ZS (Malvern Instruments, 
UK). The volume mean size of our control sample was 199.8 nm and for coating with 
0.5% F68, we got 56 nm enhancement in size which is comparable to the result obtained 
by Greenwood
82
. Figure 4 shows the size distribution of control and modified PLGA NPs 
obtained in our experiments. It was found that for 0.25 and 0.5 % poloxamer 
concentrations, the size distribution of poloxamer covered PLGA NPs shifted towards 
higher particle size region with significant simultaneous increase in volume mean particle 
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size. Santander-Ortega et al.
72
 found a sharp increase in adsorption isotherm for F68 
coating onto PLGA particles for low F68 concentration (up to 100 mg/L) and above that 
concentration, the increase was quite steady and reached a plateau. In our study, we got 
sharp increase in size up to the concentration of 0.5%. If number of poloxamer attached is 
higher, the surface will be highly crowded. Consequently, adlayer thickness increases
80
. 
Increase in poloxamer concentration from 0.5 to 1% resulted in both smaller and bigger 
particles than the control (Figure 4) indicating the formation of micelles, since the 
diameter of poloxamer micelle generally ranges from 10-200 nm as mentioned above.  
From these studies it can be concluded that the method employed to find adlayer 
depth, the surfactant and the MP/NP characteristics significantly influence the adsorption 
pattern. Relationships of adlayer thickness with MP/NP size and with poloxamer units are 
discussed in section 7. 
6. Poloxamer coated hydrophobic carriers for drug delivery 
6.1. Surface modification by poloxamer to improve drug delivery 
Hydrophobic NPs loaded with drugs when administered intravenously face quick 
clearance from body system. They are cleaned by MPS and end up in spleen/liver. Thus, 
hydrophobicity of drug carriers limits their use in pharmaceutical fields. Short lifetime of 
hydrophobic drug carriers can be increased by modifying their surface, which will yield “stealth” 
particles and would not be detected by MPS
10, 83
. Poloxamers are well applicable for this purpose.  
The PPO blocks of poloxamers is capable of attaching the hydrophobic polymeric 
surfaces and the PEO blocks, which are extended outside the surface of hydrophobic polymeric 
surfaces, transforming the surface of drug loaded hydrophobic NPs hydrophilic to make NPs 
stealth. As a result, the MPS fails to recognize the NPs due to their hydrophilic nature. 
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The fact can be lightened more explicitly with the Figures 5 and 6. PLGA NPs which are 
one of the most widely used hydrophobic drug carriers has been selected in the figures as an 
example. PLGA NPs form negatively charged surfaces in solution since they have carboxyl group 
in their structure (Figure 5a). These negatively charged drug loaded hydrophobic PLGA NPs 
adsorb plasma proteins after intravenous administration. For example, human serum albumin 
(HSA) will be adsorbed on PLGA NPs according to Figure 5b. Plasma protein adsorption 
enlarges the size of hydrophobic drug carrier particles. As a result, the particles will be visible to 
macrophages and will be removed quickly from the bloodstream. Poloxamer is adsorbed on the 
surface of a PLGA NP according to the mechanism shown in Figure 6a and protein adsorption is 
prevented by the mechanism shown in Figure 6b. As mentioned before poloxamer coating will 
make the particle “stealth” and macrophages will not be able to detect and engulf the particle. 
Due to the quick detection of drug loaded particles by macrophages, they are 
engulfed by macrophages and removed quickly from the blood stream. Hence, they 
cannot reach the target site(s) or don’t get sufficient time to release the drug, which will 
lead no effect of medication. Poloxamers, when adsorbed onto hydrophobic drug carriers, 
can depress quick clearance of those carriers from the blood stream. This is an essential 
point especially in case of targeted and sustained drug delivery. Adsorption of 
poloxamers onto the hydrophobic particles yields hydrophilic surface possessing reduced 
surface charge. The formation of such a surface not only limits the adsorption of opsonins 
resulting in extended circulation in the plasma, but also increases possible distribution to 
different organ sites. It can be mentioned here that opsonins are any blood serum 
component that aid in the process of phagocytic recognition. Opsonization is the process 
by which foreign particle(s) or organism(s) becomes covered with opsonin proteins, 
thereby making it more visible to phagocytic cells
84
. Phagocytosis can occur after 
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opsonization. Phagocytosis is the engulfing and eventual destruction or removal of 
foreign materials from the bloodstream. For non-biodegradable polymeric NPs, 
accumulation of particles in organs (most commonly the liver and spleen) can lead to 
toxicity and other negative side effects
83, 85, 86
. 
 
6.2. Poloxamer to depress quick clearance from the blood stream 
 Illum and Davis
87
 coated the surface of hydrophobic PS with poloxamer. 
If the PS was coated with P188, significantly higher amount of particles can get to the 
lung. P338 coated particles show high-level in lungs, carcass and spleen. The effect of the 
used P188 and P338 with different Mw and characteristics was investigated. Hydrophilic 
NPs/MPs having high Mw P338 coating showed appropriate colloidal stability with very 
low adhesive-properties
88
. Hence, high Mw poloxamer (P338) has better effectivity when 
compared to those with lower Mw.  
Illum et al.
86
 studied phagocytic uptake of PS coated with poloxamers. In general 
it was found that the higher the adlayer thickness, the lower the relative phagocytic 
uptake as shown in Figure 7
74
.  
These results are in agreement with the predictions of the various theories that 
explain the phenomenon of steric stabilization which can also be applied to the 
interaction of particles with phagocytic cells. It can be observed if the regression line 
(Figure 7) is extrapolated to zero, an adlayer of 23 nm thick will be needed to get over 
van der Waals attractive forces between macrophages and 5.25 µm MPs. Prediction of 
adlayer thickness, needed to achieve equal stabilizing effect for little NPs (e.g. 60nm), is 
not very easy. Van der Waals attractive force has direct relation to particles radii (a). 
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According to the equation (1) it is expected that a 10 nm thick adsorbed layer will be 
enough for providing both steric stabilization of 60 nm PS particles in terms of their 
aggregative propensity and a lack of interaction with macrophages
86
: 
 
 
where, VA = van der Waals attractive forces. 
 a = particles radii.  
Aeff = composite Hamaker constant. 
h = Planck’s constant. 
Phagocytosis of PS latex particles coated with 22 different poloxamers was 
studied by Rudt et al.
89
. A tendency was found for reduction of phagocytic uptake for 
poloxamers coated particles if Mw is more than 4000. This is obviously a generalization, 
although few exceptions were observed, notably poloxamer 108 and 333. They had the 
same Mw but different relative phagocytic uptakes (94.5% and 3.3%, respectively). When 
considering poloxamers with the same PPO chain length, variations in hydrophilic PEO 
chain length did not seem to show significant effect on phagocytic uptake. As an 
example, relative phagocytic uptakes of poloxamers 331,333,334,335, and 338 were 22.9, 
3.3, 2.5, 7.2 and 6.0 %, respectively. However, great effect is observed for PPO chain 
length variation. If more than 39 units are present in PPO chains, better protection against 
phagocytosis is observed, which might be because of more secure adsorption onto 
particle surfaces. The secure adsorption is capable of preventing displacement of the 
adsorbed poloxamer very well by other species, thus limiting the phagocytosis of drug 
carriers. Another reason which imparts a little part in this mechanism is steric 
)1(
12
−−−−−−−−−−−≈
h
aA
AV
eff
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stabilisation effects. However, too short PEO chains cannot provide sufficient 
hydrophilicity to the surface of the drug carrier to prevent opsonisation, and there exists 
possibility of steric stabilization as well. Finally, it was concluded that a PPO block of 
about 40 units will be the minimum length for achieving great decrease or preventing 
phagocytosis (Figure 8). This type of minimum length can be required for strong 
anchoring of poloxamers onto drug carrier surface which will provide enough thickness 
and hydrophilicity. 
Thus, a conclusion can be drawn: poloxamers adsorption onto hydrophobic 
polymeric drug carrier surfaces produces hydrophilic surfaces reducing surface-charge. 
These sufficiently hydrophilic particles can prevent opsonisation, which in turns increase 
the life time of carrier particles in blood circulation as well as giving the possibility of 
distribution to different organ sites. 
 
6.3 Drug delivery and release profile from poloxamer coated drug carriers 
Poloxamer coating is capable to generate higher residence time in the plasma than 
uncoated NPs
90, 91, 92
. Fluorescently labelled PLGA particles coated with PEG and 
Pluronic F127 had higher plasma concentration than the uncoated ones while used in oral 
formulations
90
. PLGA carriers without poloxamer coating were detected in the brain, 
heart, liver, spleen, lungs and kidneys over a period of 7 days. Interestingly, not even a 
single particle was detected in the plasma in the lack of surface functionalization. The 
biodistribution profile for 1% F127 and PEG coated particles administered orally is 
shown in Figure 9. Though NPs were accumulated in spleen and brain, the NPs in these 
tissues at high doses were established to be safe
91
. 
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Loperamide, an opioid drug cannot cross the blood brain barrier (BBB) although 
effective as antinociceptive if injected directly to the brain. P188-coated PLGA-PEG-
PLGA (PEP) triblock copolymer NPs containing the drug showed 14.4 to 21.2% 
penetration
93
, which was much higher than either with PLGA NPs (4.3%) or with PEP 
NPs (8.2%). The in vitro BBB permeation percentage of PEP obtained was 13.7 folds 
higher than just the loperamide solution. It shows that PEP is capable of encapsulating 
and transporting drugs across BBB which is normally impossible. Moreover, P188 coated 
PEP resulted in improved cellular uptake in BBB model compared to PEP coated with 
polysorbate80 (Ps80). Biopsy studies also confirmed increased penetration for P188 
coated PEP over non-coated one. In brain tissue(s), NPs deposition for PEP coating with 
P188 showed significantly higher concentration than both PEP and PLGA NPs. Maximal 
possible antinociception effect (MPE) for the P188-coated PEP was 21 to 35 % after 2 
and half hours of intravenous loperamide administration whereas that of just the PEP was 
11.6%. 
Various proteins quickly attach onto foreign NPs after being exposed to serum or 
plasma
94,95
. The type and the relative amount of adsorbed proteins can decide the fate of 
particles. In 1989, this concept was originally defined as “differential protein 
adsorption”
95
. Based on this concept, the hypothesis was postulated that an adsorption of 
the ApoE or ApoB (apolipoprotein E or B) on Ps80-coated NPs could be responsible for 
the interaction with the BBB and the subsequent endocytosis
95, 96, 97
. ApoE attaches the 
particles to the ApoE receptor of the endothelial cells of the BBB
98
. As a result, the 
particles are taken up by endocytosis into the cells. In the cells, the drug is released from 
the particle and diffuses into the surrounding brain tissue. Schematically the brain uptake 
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of surfactant coated NPs can be illustrated as shown in Figure 10, which is based on 
endocytosis. 
Hydrophobic polybutyl cyanoacrylate (PBCA) is an effective drug carrier. PBCA 
and PLGA NPs having P188 coating loaded with doxorubicin (Dox) appears to be 
interesting and hopeful for treating brain tumors. These NPs yield 40% of long-term 
survivors. P188 was an effective coating agent for both PLGA and PBCA NPs. However, 
coating with Ps80 showed effectiveness only for PBCA and not for PLGA NPs
99
. Ps80- 
and P188-coated PBCA loaded with Dox NPs for anti-tumor effect resulted in 35% and 
20 % of long-term survivors. 
Recently, seven different formulations including Dox was evaluated according to 
their anti-tumor efficacy
100
. All formulations increased the survival time in brain tumor-
containing specimens by comparing with control one that is shown in Figure 11. 
Poloxamer (P188) containing formulations represented the highest effectiveness. Long-
term remission (more than 100 days without tumor) in 40% of the specimens could be 
achieved. Dox-PLGA having P188/Ps80 resulted in more than 20% of long-term 
survivors
101, 102, 103
. Nevertheless, the efficacy of uncoated NPs (without poloxamer and 
polysorbate) was almost the same like Dox–solution. For uncoated NPs, just a single 
specimen survived after day 30. Free Dox concentration in the brain remained below the 
detection limit of 0.1 µg/ml. Dox concentration delivered to the brain by Ps80 coated 
PBCA NPs was found to be comparatively very high (6 µg/g tissue), showing 
significantly improved Dox-delivery to the brain because of used coating material
104
. 
Stabilizers yielded NPs of similar size
103
, although dextran-stabilized PBCA NPs had 
higher polydispersity and less negative surface charge enabling higher loading of Dox. 
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On the other hand, drug-loaded P188-stabilized NPs showed lower drug loading (45% for 
P188 and 65% for dextran) than that of dextran-stabilized particles. 
Cytotoxicity of Dox loaded PBCA NPs, coated with Ps80, P188 or poloxamine 
908 pharmaceutical surfactants was investigated in rat glioma cell lines
105
. Drug 
accumulation determined by confocal scanning microscopy revealed higher accumulation 
of nanoparticle-bound Dox after coating the particle surface with Ps80, which 
corroborated the results of the previous studies. Nanoparticle-associated Dox showed a 
higher cytotoxicity than the free drug in both tests, when the Ps80 was used to coat the 
NPs. On the other hand, P188 and poloxamine 908 showed negligible influences. This 
phenomenon can be attributed to more efficient transport of the Ps80-coated NPs into the 
cells. 
Poloxamer is able to totally inhibit protein adsorption onto the PLGA 37.5/25 
layer
106
. When P188 was present in the formulation, it exhibited a continuous release of 
lysozyme over 3 weeks without any burst effect (Figure 12). After 3 weeks, a plateau was 
reached due to additional destabilising mechanisms concomitant with polymer 
degradation. To promote the release of lysozyme in the latter stage of release, a PEP 
triblock copolymer was used, which resulted in continuous lysozyme release over 45 
days in a biologically active form with limited initial burst (9%). Considering the 
wettability of the polymer, after 45 days the poloxamer and the PEG segments are 
leached thereby limiting their protective function, and according to the adaptation of 
hydration kinetics, the microspheres might provide optimal protein release. 
As a summary, the investigations undoubtedly indicate the protein adsorption 
hindrance and thus, possibility of achieving prolonged residence time in the bloodstream 
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using poloxamer surfactants even via oral administration. Detection of the comparatively 
high amount of NPs in kidney, lungs and liver might be because of nonhomogeneous 
attachment of coating agents onto NPs. Poloxamers have the ability to (i) be incorporated 
into membranes and to change microviscosity (ii) decrease ATP (Adenosine 
triphosphate) levels (iii) resist drug efflux transporters, which might result in enhanced 
penetration and drug transport through the BBB. These features help the efficient use of 
microencapsulated active agents functionalized with poloxamers in controlled drug 
delivery systems. It is noted that results suggest that for NP formulations in vitro 
observations cannot easily correlate or represent the in vivo behavior of the NPs. 
 
7. Correlation of particle size, poloxamer units, adlayer thickness and drug release 
7.1. Effect of particle size on adlayer thickness 
A small particle adsorbs less polymeric molecules per unit area in comparison to a 
large one resulting in lower thickness than larger particles as shown in Figure 13
55
. This 
can be also explained by the following equation showing how the surface area filled by 
unit poloxamer molecule depends on the particle diameter 
54
: 
 
BA
A
mN
MWd
Molecule
areaSurface
2
π
=  
where dA = diameter of core NP or MP 
MW = molecular weight of adsorbed poloxamer 
mB = mass of adsorbed poloxamer 
NA = Avogadro's number. 
From the equation it can be seen that the surface area covered by poloxamer is directly 
proportional to the square of the diameter of core NP or MP (dA). 
The thickness of the adsorbed poloxamers to PS MPs was studied using field flow 
fractionation technique, and it was found that the thickness increases with particle size
54
. 
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The thickness increased from 60 nm to 270 nm applying F108, F88, F68 coating but not 
for P105
77
. As a contrary, Baker and Berg
76
 and Killmann et al.
107
 measured adlayer 
thickness of poloxamer on PS particles using PCS. They found that the adsorption does 
not depend on the particle size, and the adlayer thickness decreases with increasing 
NPs/MPs radii. For adsorption of F108 on PS, Bevan et al.
108
 has quoted 12 nm and 15 
nm thick adlayer onto 140 nm and 400 nm NPs, respectively. Greenwood et al.
82
 found 
strong size dependence of adlayer thickness for P407 onto PS NPs. The adlayer showed a 
tendency to increase from 11 nm to 37 nm onto NPs of size 40 nm and 217 nm, 
respectively. Li et al.
54
 observed strong dependence of surface concentration and 
adsorbed layer thickness on substrate size. On little PS-latex (69 nm), poloxamer 
adsorption layer was almost double thick of radius of gyration (Rg) of its PEO blocks. On 
the other hand, for bigger size (272 nm PS), PEO blocks showed large extension and 
adlayer was about 4Rg thick. On small particles, the surface-density of adsorbed 
polymeric molecules is little. The consequence is highly mobile adsorbed polymer 
chains. Conversely, on large particles, the adlayer is mobile to a lesser extent due to more 
crowded surface. An adsorbed polymeric chain moves more freely if surface packing is 
less (little NPs/MPs) in comparison to highly dense packing (big NPs/MPs).  
 
7.2. Effect of units of the poloxamers on adlayer thickness 
Adlayer thickness strongly depends on EO units and not influenced by PO 
number
73
. Figure 14 depicts the direct dependence of adlayer depth on EO and PO 
content. This is the indication that the PO adsorption occurs on substrate surface whereas 
looping or tailing is observed due to the extension of EO to aqueous phase. This can be 
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more clearly understood from the Table 4 obtained by Illum et al.
73
 who studied 
adsorption of poloxamer on polystyrene particles. P338 having 128 EO units gives 15.8 
nm adlayer thickness whereas P188 having 75 EO units gives less thick adlayer (7.6 nm). 
This result is in agreement with the one found by Kayes et al.
74
. Faers
81
 observed increase 
in adlayer thickness for enhancement of Mw of PEO chain. 
 
7.3. Effects of the adlayer thickness on release profile 
The release pattern depends on many factors e.g. matrix structure, type of drug 
loaded, size of drug molecules, distribution of drug molecules inside the matrix, etc. It is 
known that drug loading and drug particle size distribution determine the geometry and 
the topology of pores and channels which determine drug diffusion from the hydrophobic 
matrix
109
. It is not an easy task to make a correlation between the coating thickness and 
the release profile for drug loaded NPs and MPs. Only the coated layer covering the 
surface i.e. PPO block affects the release profile. Nano- and microparticle surfaces are 
porous and may also contain cracks which originate from fabrication process. Drugs 
escape from the polymeric matrices through the cracks and pores. Poloxamer, used for 
coating, may cover many of the pores (not all of them). After surface covering, the coated 
portion will prevent diffusion of drug and initial burst release. 
The prevention of the drug diffusion has direct effect on the drug release. If the 
diffusion is low, the drug release time will be extended. On the other hand, PEO blocks 
extends to the outer aqueous phase and make the particles stealth to macrophages. It can 
be assumed that they do not have direct effect on the release profile. However, if the 
extended chain length of PEO is not sufficiently thick, they won’t be able to prevent 
protein adsorption on the particle surface as shown in Figure 6b. It is well known that the 
drug release rates decrease with increasing coating thickness due to enhanced length of 
diffusion pathways for tablet coating, which cannot be applied directly for poloxamer 
coating, nevertheless, it can provide an approximation for estimating the poloxamer 
effect. In addition, the surface coating will decrease the initial burst release
110
.  
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Diffusion-controlled drug release from matrix-type drug-delivery systems can be 
expressed by the popular equation given by Higuchi
111
,  
τ
εε tCCCD
AM
sdsi
t
)2( −
=  
where Mt is the drug amount released at time t, A is the surface area of the matrix, Di is 
the diffusivity of the drug, ε is the porosity of the matrix, τ is tortuosity of the matrix, Cs 
is the solubility, Cd is the concentration of the drug. 
Poloxamer attachment increases the size of NPs and MPs. Consequently, surface area A 
will decrease, and smaller value of Mt, i.e. lower drug release will be obtained. 
 
8. Conclusion 
Poloxamers are triblock copolymers having amphiphilic character and have the 
ability to interact with hydrophobic drug carrier surfaces and biological membranes. Drug 
carriers are confronted with difficulties during the route to the target organ that need to 
overcome before they reach its target site(s) within the body. The most important barrier 
is the adsorption of plasma proteins which make them more visible to phagocytic cells, 
then, they are immediately engulfed by macrophages and removed quickly from the 
blood stream. Poloxamer coating makes hydrophobic carriers “stealth”, hence they can 
reach the target site(s), where they can perform their biological roles. Poloxamers are 
adsorbed onto hydrophobic carriers by their PPO block, whereas PEO block is extended 
toward the aqueous dispersant and make the surface of the carrier hydrophilic. The 
adsorption pattern and the adlayer thickness are strongly affected by the nature of the 
surface of carrier particles. The concentration of poloxamer is also vital since the adlayer 
thickness and thus the final size of drug carriers generally show the tendency to grow 
with the increase in poloxamer concentration. The particle size also influences the 
adlayer thickness, since the smaller particles take up fewer poloxamer molecules per unit 
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area than the larger ones, and in turn show lower thickness than the adlayer found on 
bigger particles. Poloxamer coated stealth carriers possess increased life time in the blood 
stream and show decreased phagocytic uptake. Most widely investigated biodegradable 
polymers for drug delivery, PLGAs show excellent life time in the blood stream after 
being coated by poloxamers. In vitro and in vivo studies certified that improved drug 
delivery and better release profile can be obtained from poloxamer coated drug carriers. It 
is expected that in the future more in vivo studies will be conducted, and more clinical 
trials will be performed to utilize promising coating agent poloxamer in the field of drug 
delivery.  
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Abbreviations 
Apo = apolipoprotein  
BBB = blood brain barrier 
CMC = critical micelle concentration  
Dox = doxorubicin  
EPR = enhanced permeability and retention  
HLB = hydrophilic-lipophilic balance 
Mw = molecular weight 
MPS = mononuclear phagocytic system 
MPs = microparticles 
NPs = nanoparticles 
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PBCA = poly(butyl cyanoacrylate) 
PEG = poly(ethylene glycol) 
PLGA = poly(lactide-co-glycolide) 
PLGA-PEG-PLGA = PEP 
P188 = poloxamer 188 
P338 = poloxamer 338  
P407 = poloxamer 407 
F88 = Poloxamer 238 
PS = polystyrene 
Ps80 = polysorbate 80 
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Legends of Figures 
Figure 1: Structure of poloxamer. 
Figure 2: Schematic representation of poloxamer adsorption onto hydrophobic drug 
carrier surfaces: (a) PPO binds with carrier surface and PEO block extends to outer 
phase; (b) "brush-type" conformation and (c) "mushroom-type" conformation
54
. 
Figure 3: Adsorption isotherms for P407 on PS NPs. Particle diameters: 40 nm (♦), 71 nm 
(■) and 137nm (▴) (Taken from Ref. 79, with permission from American Chemical 
Society, Copyright 2001).  
Figure 4: Size distribution of uncoated PLGA and (0.25 %, 0.5 %, 1 %) poloxamer 
coated PLGA NPs. 
Figure 5: (a) a negatively charged hydrophobic drug carrier PLGA NP (b) adsorption of a 
plasma protein e.g. HSA onto a PLGA NP. 
Figure 6: (a) a poloxamer coated PLGA NP (b) prevention of protein adsorption onto a 
PLGA NP by poloxamer coating. 
Figure 7: Relationship among thickness of the coating layer of poloxamers and 
poloxamine on PS particles and their relative phagocytic uptake by mouse peritoneal 
macrophages (Taken from Ref. 73, with permission from Elsevier, Copyright 1987).  
Figure 8: Relative phagocytic uptake (AUC) of 3190 nm particles by human granulocytes 
coated with poloxamer polymers with increasing length of the PPO center part (22 
different poloxamer) (Taken from Ref. 89, with permission from Elsevier, Copyright 
1993).  
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Figure 9: Biodistribution of Rhodamine labelled PLGA NPs. Days: (A) One; (B) Three; 
(C) Seven (after oral administration). (Taken from Ref. 90, with permission from 
Elsevier, Copyright 2012).  
Figure 10: Schematic representation of the probable mechanism of surfactant coated NP’s 
brain uptake. Drug releases from NPs upon endocytosis through the BBB endothelial 
cells. 
Figure 11: Kaplan–Meier survival plot of rats with intracranially transplanted 101/8 
glioblastoma after intravenous administration of doxorubicin formulations (n = 10–12) 
(Taken from Ref. 100, with permission from Elsevier, Copyright 2010).  
Figure 12: In vitro release profile of lysozyme from PLGA MPs without P188 (×) (n = 2 
batches, twice) and with P188 (△) (n = 3 batches) and from PLGA–PEG–PLGA MPs 
containing P188 (□) (n = 7 batches) (Taken from Ref. 106, with permission from 
Elsevier, Copyright 2010).  
Figure 13: Curvature-dependent adlayer thickness for poloxamers (Taken from Ref. 54, 
with permission from American Chemical Society, Copyright 1994). 
Figure 14: Relation among coated layer thickness and EO units for PS MPs. Coating 
agents: poloxamers and poloxamine (Taken from Ref. 73, with permission from Elsevier, 
Copyright 1987). 
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Legends of Tables 
 
Table1: Parameters of poloxamers which are discussed in this review. 
Table 2: Adsorption pattern of P407 onto 40, 70 and 137 nm PS NPs
79
. 
Table 3: Points of adsorption isotherm for P407 adsorption onto 40 nm PS NPs showing 
hydrodynamic layer thickness and others
79
. 
Table 4: Thickness of adlayer for different poloxamers having different EO and PO 
units
73
. 
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Table 1: Some propertiesParameters of poloxamers (only those which are discussed in 
this review). 
Copolymer 
 
Molecular 
Weight 
Critical micelle 
concentration 
(CMC)
a
 (M)  
Average 
no. of EO 
units (x)
b
 
Average 
no. of PO 
units (y)
b
 
hydrophilic
-lipophilic 
balance  
L35 (Poloxamer 105) 1900 5.3×10
-3
 21.59 16.38 19 
F68 (Poloxamer 188)  8400 4.8×10
-4
 152.73 28.97 29 
F88 (Poloxamer 238) 11400 2.5×10
-4
 207.27 39.31 28 
L101 (Poloxamer 331) 3800 2.1×10
-6
 8.64 85.97 1 
P103 (Poloxamer 333) 4950 6.1×10
-6
 33.75 59.74 9 
P104 (Poloxamer 334) 5900 3.4×10
-6
 53.64 61.03 13 
P105 (Poloxamer 335) 6500 6.2×10
-6
 73.86 56.03 15 
F108 (Poloxamer 338) 14600 2.2×10
-5 
265.45 50.34 27 
F127 (Poloxamer 407) 12600 2.8×10
-6
 200.45 65.17 22 
a
CMC values obtained with the use of pyrene probe
24
. 
b
The average numbers of EO and PO units were calculated using the average molecular 
weights. 
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Table 2: Adsorption pattern of P407 onto 40, 70 and 137 nm PS NPs
797
. 
Particle size 
(nm) 
Average amount 
adsorbed 
(µmol/m
2
) 
Average amount 
adsorbed 
(mg/m
2
) 
Hydrodynamic 
layer thickness 
(nm) 
137 0.19±0.02 2.4±0.2 7.7±0.5 
70 0.16±0.04 2.0±0.5 7.7±0.3 
40 0.18±0.03 2.3±0.3 8.5±0.1 
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Table 3: Points of adsorption isotherm for P407 adsorption onto 40nm PS NPs showing 
hydrodynamic layer thickness and others
797
.  
Amount 
adsorbed 
(mg/m
2
) 
Amount 
adsorbed 
(nmol/m
2
) 
Hydrodynamic 
layer thickness 
(nm) 
Average 
area per 
molecule 
(nm
2
) 
Average 
area per 
PEO chain 
(nm
2
) 
Surface 
coverage 
(%) 
0.097 7.72 1.23 215 107.5 4 
0.23 18.3 1.33 90.7 45.4 10 
0.608 48.3 4.03 34.4 17.2 26 
0.869 69 6.22 24.1 12 37 
1.173 93.1 5.88 17.8 8.9 50 
1.1449 115 6 14.4 7.2 63 
2.293 182 8.32 9.12 4.5 100 
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Table 4: Average size of PLGA NPs coated with poloxamer F68.  
Percentage of poloxamer  Size (nm) 
0% (control)  199.8 
0.25% F68 207.4 
0.5% F68 256.3 
1% F68 201.3 
 
Table 4: Thickness of adlayer for different poloxamers having different EO and PO 
units
73
. 
 
Type of 
poloxamer 
Molecular block average values (mol) Thickness of 
adlayer (nm) EO PO EO 
P188 75 30 75 7.6 
F88 97 39 97 13.2 
P338 128 54 128 15.8 
P407 98 67 98 15.4 
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Figure 1: Structure of poloxamer.  
189x87mm (96 x 96 DPI)  
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Figure 2: Schematic representation of poloxamer adsorption onto hydrophobic drug carrier surfaces: (a) PPO 
binds with carrier surface and PEO block extends to outer phase; (b) "brush-type" conformation and (c) 
"mushroom-type" conformation54.  
569x179mm (96 x 96 DPI)  
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Figure 3: Adsorption isotherms for P407 on PS NPs. Particle diameters: 40 nm (♦), 71 nm (■) and 137nm (▴) 
(Taken from Ref. 79, with permission from American Chemical Society, Copyright 2001).  
552x300mm (96 x 96 DPI)  
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Figure 4: Size distribution of uncoated PLGA and (0.25 %, 0.5 %, 1 %) poloxamer coated PLGA NPs.  
411x111mm (96 x 96 DPI)  
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Figure 5: (a) a negatively charged hydrophobic drug carrier PLGA NP (b) adsorption of a plasma protein e.g. 
HSA onto a PLGA NP.  
614x240mm (96 x 96 DPI)  
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Figure 6: (a) a poloxamer coated PLGA NP (b) prevention of protein adsorption onto a PLGA NP by 
poloxamer coating.  
569x258mm (96 x 96 DPI)  
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Figure 7: Relationship among thickness of the coating layer of poloxamers and poloxamine on PS particles 
and their relative phagocytic uptake by mouse peritoneal macrophages (Taken from Ref. 73, with permission 
from Elsevier, Copyright 1987).  
390x257mm (96 x 96 DPI)  
 
 
Page 54 of 61
URL: http://mc.manuscriptcentral.com/LMSC  Email: patrick.mather@gmail.com
Polymer Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
Figure 8: Relative phagocytic uptake (AUC) of 3190 nm particles by human granulocytes coated with 
poloxamer polymers with increasing length of the PPO center part (22 different poloxamer) (Taken from Ref. 
89, with permission from Elsevier, Copyright 1993).  
357x306mm (96 x 96 DPI)  
 
 
Page 55 of 61
URL: http://mc.manuscriptcentral.com/LMSC  Email: patrick.mather@gmail.com
Polymer Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
Figure 9: Biodistribution of Rhodamine labelled PLGA NPs. Days: (A) One; (B) Three; (C) Seven (after oral 
administration). (Taken from Ref. 90, with permission from Elsevier, Copyright 2012).  
516x829mm (96 x 96 DPI)  
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Figure 10: Schematic representation of the probable mechanism of surfactant coated NP’s brain uptake. 
Drug releases from NPs upon endocytosis through the BBB endothelial cells.  
973x343mm (96 x 96 DPI)  
 
 
Page 57 of 61
URL: http://mc.manuscriptcentral.com/LMSC  Email: patrick.mather@gmail.com
Polymer Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
Figure 11: Kaplan–Meier survival plot of rats with intracranially transplanted 101/8 glioblastoma after 
intravenous administration of doxorubicin formulations (n = 10–12) (Taken from Ref. 100, with permission 
from Elsevier, Copyright 2010).  
397x294mm (96 x 96 DPI)  
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Figure 12: In vitro release profile of lysozyme from PLGA MPs without P188 (×) (n = 2 batches, twice) and 
with P188 (△) (n = 3 batches) and from PLGA–PEG–PLGA MPs containing P188 (□) (n = 7 batches) (Taken 
from Ref. 106, with permission from Elsevier, Copyright 2010).  
278x285mm (96 x 96 DPI)  
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Figure 13: Curvature-dependent adlayer thickness for poloxamers (Taken from Ref. 54, with permission 
from American Chemical Society, Copyright 1994).  
338x251mm (96 x 96 DPI)  
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Figure 14: Relation among coated layer thickness and EO units for PS MPs. Coating agents: poloxamers and 
poloxamine (Taken from Ref. 73, with permission from Elsevier, Copyright 1987).  
411x285mm (96 x 96 DPI)  
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